The affordable versions of the blockbuster drug are expected to hit the market this month and reportedly reduce the cost of the therapy by nearly half. A blockbuster heart failure drug by Swiss pharma major Novartis is going off-patent in January this year. Several pharmaceutical industry experts told Financial Express.com that the patent loss of Vymada or Entresto is set to cause major disruptions in India’s cardiology sector. Read more here..